Group 1 - The core viewpoint of the news highlights the trading performance and financing activities of He Yuan Biological Technology Co., Ltd. on October 9, with a stock price increase of 4.19% and a trading volume of 285 million yuan [1] - On October 9, the financing buy-in amount for He Yuan Biological was 25.19 million yuan, while the financing repayment was 27.92 million yuan, resulting in a net financing buy-in of -2.73 million yuan [1] - As of October 9, the total margin balance for He Yuan Biological was 153 million yuan, which accounts for 2.90% of its circulating market value, indicating a low financing balance compared to the past year [1] Group 2 - He Yuan Biological, established on March 5, 2013, and listed on March 22, 2022, specializes in providing CRO services for gene therapy and CDMO services for gene drug development [2] - The company's main business revenue composition includes 54.75% from cell and gene therapy CDMO services, 33.96% from CRO services, 10.28% from bioreagents and other services, and 1.02% from regenerative medicine services [2] - For the period from January to June 2025, He Yuan Biological achieved an operating income of 120 million yuan, representing a year-on-year growth of 6.01%, while the net profit attributable to shareholders was -105 million yuan, showing a year-on-year increase of 7.74% [2]